• 1.

    Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, Birmingham M, Glass RI, 2009. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 200 (Suppl 1): S9S15.

    • Search Google Scholar
    • Export Citation
  • 2.

    Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD; WHO-coordinated Global Rotavirus Surveillance Network, 2012. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 12: 136141.

    • Search Google Scholar
    • Export Citation
  • 3.

    de Oliveira LH, Danovaro-Holliday MC, Sanwogou NJ, Ruiz-Matus C, Tambini G, Andrus JK, 2011. Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience. Pediatr Infect Dis J 30 (Suppl): S61S66.

    • Search Google Scholar
    • Export Citation
  • 4.

    WHO, 2008. Estimated Rotavirus Deaths for Children Under 5 Years of Age: 2008. Available at: http://wwwwhoint/immunization/monitoring_surveillance/burden/estimates/rotavirus/en/.

    • Search Google Scholar
    • Export Citation
  • 5.

    WHO, 2009. Rotavirus vaccines: an update. Wkly Epidemiol Rec 84: 533537.

  • 6.

    Atherly DE, Lewis KD, Tate J, Parashar UD, Rheingans RD, 2012. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011–2030. Vaccine 30 (Suppl 1): A7A14.

    • Search Google Scholar
    • Export Citation
  • 7.

    Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, Espinoza F, López P, Macías-Parra M, Ortega-Barría E, Rivera-Medina DM, Rivera L, Pavía-Ruz N, Nuñez E, Damaso S, Ruiz-Palacios GM, De Vos B, O'Ryan M, Gillard P, Bouckenooghe A; Human Rotavirus Vaccine Study Group, 2008. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371: 11811189.

    • Search Google Scholar
    • Export Citation
  • 8.

    Rheingans RD, Constenla D, Antil L, Innis BL, Breuer T, 2007. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries. Revista Panam Salud Publica 21: 205216.

    • Search Google Scholar
    • Export Citation
  • 9.

    Steenland MW, Joseph GA, Lucien MA, Freeman N, Hast M, Nygren BL, Leshem E, Juin S, Parsons MB, Talkington DF, Mintz ED, Vertefeuille J, Balajee SA, Boncy J, Katz MA, 2013. Laboratory-confirmed cholera and rotavirus among patients with acute diarrhea in four hospitals in Haiti, 2012–2013. Am J Trop Med Hyg 89: 641646.

    • Search Google Scholar
    • Export Citation
  • 10.

    Mijatovic-Rustempasic S, Tam KI, Kerin TK, Lewis JM, Gautam R, Quaye O, Gentsch JR, Bowen MD, 2013. Sensitive and specific quantitative detection of rotavirus A by one-step real-time reverse transcription-PCR assay without antecedent double-stranded-RNA denaturation. J Clin Microbiol 51: 30473054.

    • Search Google Scholar
    • Export Citation
  • 11.

    Hull JJ, Teel EN, Kerin TK, Freeman MM, Esona MD, Gentsch JR, Cortese MM, Parashar UD, Glass RI, Bowen MD; National Rotavirus Strain Surveillance System, 2011. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 30 (Suppl): S42S47.

    • Search Google Scholar
    • Export Citation
  • 12.

    Levy K, Hubbard AE, Eisenberg JN, 2009. Seasonality of rotavirus disease in the tropics: a systematic review and meta-analysis. Int J Epidemiol 38: 14871496.

    • Search Google Scholar
    • Export Citation
  • 13.

    Bourdett-Stanziola L, Jimenez C, Ortega-Barria E, 2008. Diversity of human rotavirus G and P genotypes in Panama, Costa Rica, and the Dominican Republic. Am J Trop Med Hyg 79: 921924.

    • Search Google Scholar
    • Export Citation
  • 14.

    Bourdett-Stanziola L, Ortega-Barria E, Espinoza F, Bucardo F, Jimenez C, Ferrera A, 2011. Rotavirus genotypes in Costa Rica, Nicaragua, Honduras and the Dominican Republic. Intervirology 54: 4952.

    • Search Google Scholar
    • Export Citation
  • 15.

    de Oliveira LH, Danovaro-Holliday MC, Andrus JK, de Fillipis AM, Gentsch J, Matus CR, Widdowson MA; Rotavirus Surveillance Network, 2009. Sentinel hospital surveillance for rotavirus in Latin American and Caribbean countries. J Infect Dis 200 (Suppl 1): S131S139.

    • Search Google Scholar
    • Export Citation
  • 16.

    Ribas M de L, Nagashima S, Calzado A, Acosta G, Tejero Y, Cordero Y, Piedra D, Kobayashi N, 2011. Emergence of G9 as a predominant genotype of human rotaviruses in Cuba. J Med Virol 83: 738744.

    • Search Google Scholar
    • Export Citation
  • 17.

    Banyai K, Laszlo B, Duque J, Steele AD, Nelson EA, Gentsch JR, Parashar UD, 2012. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine 30 (Suppl 1): A122A130.

    • Search Google Scholar
    • Export Citation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 

 

 

Rotavirus Group A Genotypes Detected Through Diarrheal Disease Surveillance in Haiti, 2012

View More View Less
  • Centers for Disease Control and Prevention, Atlanta, Georgia; Laboratoire National de Santé Publique (National Public Health Laboratory), Port-au-Prince, Haiti
Restricted access

Samples collected in 2012 through diarrheal disease surveillance in Haiti were tested for rotavirus by enzyme immunoassay and real time RT-PCR and positive samples were genotyped. The predominant genotypes were G1P[8] (29% prevalence) and G9P[8] (21%). The observed genotype prevalence was similar to that reported previously for other Caribbean countries.

Author Notes

* Address correspondence to Michael D. Bowen, Division of Viral Diseases, NCIRD, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30333. E-mail: mkb6@cdc.gov

Authors' addresses: Mathew D. Esona, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, E-mail: mdi4@cdc.gov. Josiane Buteau, Gerard A. Joseph, and Jacques Boncy, Laboratoire National de Santé Publique, LNSP, Port-au-Prince, Haiti, E-mails: jolib2@gmail.com, gerardajo944@gmail.com, and jboncy2001@yahoo.fr. Mentor Ali Ber Lucien, Department of Microbiology, Quisqueya University, Port-au-Prince, Haiti, E-mail: lucienmentor@gmail.com. Eyal Leshem, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, E-mail: wgp9@cdc.gov. S. Arunmozhi Balajee, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, E-mail: fir3@cdc.gov. Mark A. Katz, Centers for Disease Control and Prevention Haiti, Port-au-Prince, Haiti, E-mail: markakatz@gmail.com. Michael D. Bowen, Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, E-mail: mkb6@cdc.gov.

Save